A game changer in gynecology clinical practice.
Each year, millions of women encounter gynecological health challenges, yet diagnostic approaches frequently prove inadequate, resulting in missed opportunities for timely intervention and suboptimal outcomes.
![Estimated number of new cases from 2022 to 2045, Both sexes, age [0-85+]](https://i0.wp.com/gynoaid.health/wp-content/uploads/2025/07/a5136-graphic-estimated-number-of-new-cases-from-2022-to-2045-both-sexes-age-0-85-africa-latin-america-and-the-caribbean-northern-america-europe-oceania-asia.png?ssl=1)
Life is not numbers. But numbers can lead to a better life.
Group with AI PCT pending patents
Gynecology market expected 44.8 Billion €
Providing AI-aiding tools with diagnostic accuracy over
Team with scientific publications / awards
Group with AI PCT pending patents
Gynecology market expected 44.8 Billion €
Providing AI-aiding tools with diagnostic accuracy over
Team with scientific publications / awards
Empowering Women’s Health with Comprehensive AI-Powered Solutions.
AI-powered platform ensuring over 95% accuracy in detecting and differentiating a wide range of relevant lesions lesions across the female genital tract. With immense potential to minimize diagnostic errors, accelerate the examination process.
Automatic identification and differentiation of vaginal squamous cell percursors. Overall accuracy of 95%.
Automatic identification and differentiation of vulvar squamous cell percursors. Overall accuracy of 95%.
Automatic identification and differentiation of cervical squamous cell percursors. Overall accuracy of 99%.
Automatic identification and differentiation of endometrial lesions during Hysteroscopy. Lesion delimitation with ability to guide biopsies and treatment.
Founded by passionate clinicians and engineers, our company boasts extensive expertise and unwavering determination.
Globally renowned for pioneering research and development, we’ve amassed 100+ publications and international accolades.
Focusing on AI in medicine, our R&D is esteemed and validated by peers worldwide.
Get the latest developments from our AI technologies by subscribing to our newsletter
